Article Text
PDFHow to understand it
Antisense oligonucleotides and other genetic therapies made simple
Abstract
Many genetic neurological diseases result from the dysfunction of single proteins. Genetic therapies aim to modify these disease-associated proteins by targeting the RNA and DNA precursors. This review provides a brief overview of the main types of genetic therapies, with a focus on antisense oligonucleotides (ASOs) and RNA interference (RNAi). We use examples of new genetic therapies for spinal muscular atrophy, Duchenne muscular dystrophy and familial amyloid polyneuropathy to highlight the different mechanisms of action of ASOs and RNAi.
- neurogenetics
- Rna interference
- antisense oligonucleotides
- viral gene therapy
- genome editing
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Gene therapy for neuromuscular disorders: prospects and ethics
- Spinal muscular atrophy: untangling the knot?
- A current approach to heart failure in Duchenne muscular dystrophy
- The transthyretin amyloidoses: advances in therapy
- Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy
- Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
- A 2020 centenary perspective on neuromuscular disorders
- HnRNPR strongly represses splicing of a critical exon associated with spinal muscular atrophy through binding to an exonic AU-rich element
- Duchenne muscular dystrophy: genome editing gives new hope for treatment
- Great expectations: virus-mediated gene therapy in neurological disorders